))
10 Predictions for 2024
Manage episode 393288201 series 3531512
Content provided by Matthew Weiner, MD and Zoe Schroeder, RD, Matthew Weiner, MD, Zoe Schroeder, and RD. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Matthew Weiner, MD and Zoe Schroeder, RD, Matthew Weiner, MD, Zoe Schroeder, and RD or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Could Zepbound, the latest GLP-1 medication, eclipse the success of weight loss giant Wegovy? Tune in as we dissect the burgeoning revolution in obesity treatment, where medications such as Ozempic and Mounjaro are redefining the approach to this stubborn metabolic disease. We unpack the stunning efficacy of Zepbound, debate its potential to rival bariatric surgery outcomes, and confront the crucial issue of medication accessibility. Drawing on expert insights, we offer predictions on how Zepbound might reshape the availability and affordability of weight loss treatments in the upcoming year, navigating the complexities of supply chain disturbances and pharmaceutical management.
The conversation takes a futuristic turn with the introduction of AI into the weight management arena. Imagine a world where meal planning and health resources are fine-tuned by intelligent algorithms, shaping the way consumers and healthcare providers tackle obesity. We scrutinize Novo Nordisk's supply dilemmas but offer kudos to Eli Lilly for their adept handling of Mounjaro distribution. The narrative then shifts to the adventurous—patients sourcing GLP-1 drugs from overseas to bypass insurance hurdles and the growing trend of non-diabetics using continuous glucose monitoring. We peel back the layers of these trends to reveal their implications for the future of weight loss and health management.
Lastly, we ponder the changing landscape of bariatric surgery amid the rise of GLP-1 medications, discussing the decline in surgery rates and the exciting potential for combination therapies. We also stir the pot on lifestyle shifts, spotlighting the conscious reduction in caffeine and alcohol intake for improved sleep and overall wellness. Our commitment to bringing you the latest insights in health and fitness remains unwavering. With our finger on the pulse, we promise another year of thought-provoking discussions and invaluable content that will keep you informed and motivated on your health journey.
Chapters
1. Weight Loss Trends for 2024 (00:00:00)
2. Zepbound IN, Ozempic OUT (00:01:22)
3. Keto OUT, Plant-Based IN (00:05:20)
4. Harder to get GLP-1's through Insurance (00:08:02)
5. AI Uses for Weight Loss Increase (00:12:29)
6. Lots of People will get Mounjaro from Canada (00:16:53)
7. Non-Diabetic Glucose Monitoring Becomes More Popular (00:19:27)
8. Compounded GLP-1 Meds are OUT (00:22:37)
9. Less HIIT, More Strength Training (00:25:40)
10. Bariatric Surgery + GLP-1 medications will become the Gold Standard (00:29:01)
11. People will Start Eliminating Caffeine (00:31:24)
38 episodes
Share
